Bio Symetrics, Inc. announced it raised $4.88 Million in an initial filing from an offering of $5.85 Million

Company

Location

About

BioSymetrics innovative Elion™ platform uses in silico artificial intelligence and in vivo clinical research to reduce costs and improve results at every stage drug discovery. Patent pending Contingent AI and a unique phenograph of human (EMR) and animal phenotype data improve hit identification and lead progression. BioSymetrics is Drug Discovery Accelerated.